{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:57:09Z","timestamp":1792324629531,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T00:00:00Z","timestamp":1444867200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s15010-015-0851-1","type":"journal-article","created":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T12:05:49Z","timestamp":1444910749000},"page":"291-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim\u2013sulfamethoxazole: lessons from an observational cohort study"],"prefix":"10.1007","volume":"44","author":[{"given":"Dina","family":"Creemers-Schild","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank P.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed. J.","family":"Kuijper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G. J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,15]]},"reference":[{"key":"851_CR1","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf . Accessed 18 June 2014."},{"key":"851_CR2","doi-asserted-by":"crossref","unstructured":"Walzer PD, Smulian AG. Pneumocystis species. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases, 7th ed. Philadelphia; 2010. p. 3377\u201390.","DOI":"10.1016\/B978-0-443-06839-3.00270-8"},{"key":"851_CR3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0031-1295725","volume":"32","author":"SA Gilroy","year":"2011","unstructured":"Gilroy SA, Bennett NJ. Pneumocystis pneumonia. Semin Respir Crit Care Med. 2011;32:775\u201382.","journal-title":"Semin Respir Crit Care Med"},{"key":"851_CR4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1128\/AAC.5.3.289","volume":"5","author":"WT Hughes","year":"1974","unstructured":"Hughes WT, McNabb PC, Makres TD, Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1974;5:289\u201393.","journal-title":"Antimicrob Agents Chemother"},{"key":"851_CR5","first-page":"47S","volume":"112","author":"WT Hughes","year":"1975","unstructured":"Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumocystis carinii pneumonitis with trimethoprim\u2013sulfamethoxazole. Can Med Assoc J. 1975;112:47S\u201350S.","journal-title":"Can Med Assoc J"},{"key":"851_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-105-1-37","volume":"105","author":"JM Wharton","year":"1986","unstructured":"Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, Hadley WK, Ingram-Drake L, Volberding PA, Hopewell PC. Trimethoprim\u2013sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986;105:37\u201344.","journal-title":"Ann Intern Med"},{"key":"851_CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/infdis\/170.1.165","volume":"170","author":"FR Sattler","year":"1994","unstructured":"Sattler FR, Frame P, Davis R, Nichols L, Shelton B, Akil B, Baughman R, Hughlett C, Weiss W, Boylen CT, van der Horst C, Black J, Powderly W, Steigbigel RT, Leedom JM, Masur H, Feinberg J. Trimetrexate with leucovorin versus trimethoprim\u2013sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029\/031. J Infect Dis. 1994;170:165\u201372.","journal-title":"J Infect Dis"},{"key":"851_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00002030-199203000-00007","volume":"6","author":"NC Klein","year":"1992","unstructured":"Klein NC, Duncanson FP, Lenox TH, Forszpaniak C, Sherer CB, Quentzel H, Nunez M, Suarez M, Kawwaff O, Pitta-Alvarez A, Freeman K, Wormser GP. Trimethoprim\u2013sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992;6:301\u20135.","journal-title":"AIDS"},{"key":"851_CR9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/0003-4819-124-9-199605010-00003","volume":"124","author":"S Safrin","year":"1996","unstructured":"Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, Cheung T, Soeiro R, Hojczyk P, Black JR. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim\u2013sulfamethoxazole, dapsone\u2013trimethoprim, and clindamycin\u2013primaquine. ACTG 108 Study Group. Ann Intern Med. 1996;124:792\u2013802.","journal-title":"Ann Intern Med"},{"key":"851_CR10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","volume":"328","author":"W Hughes","year":"1993","unstructured":"Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C, Lavelle J, Rosenstock J, Falloon J, Feinberg J, Lafon S, Rogers M, Sattler F. Comparison of atovaquone (566C80) with trimethoprim\u2013sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521\u20137.","journal-title":"N Engl J Med"},{"key":"851_CR11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3109\/00365540903214256","volume":"41","author":"M Thomas","year":"2009","unstructured":"Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10\u00a0mg\/kg\/day\u2013sulfamethoxazole 50\u00a0mg\/kg\/day for Pneumocystis jirovecii pneumoniae in HIV infected patients. Scand J Infect Dis. 2009;41:862\u20138.","journal-title":"Scand J Infect Dis"},{"key":"851_CR12","first-page":"593","volume":"21","author":"FJ Bowden","year":"1991","unstructured":"Bowden FJ, Stewart K, Mashford L, Lucas CR. A randomised, double blind trial of low dose versus high dose cotrimoxazole in the treatment of aids-related Pneumocystis carinii pneumonia. Aust N Z J Med. 1991;21:593.","journal-title":"Aust N Z J Med"},{"key":"851_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2796.1990.tb00172.x","volume":"227","author":"JK Eeftinck Schattenkerk","year":"1990","unstructured":"Eeftinck Schattenkerk JK, Lange JM, van Steenwijk RP, Danner SA. Can the course of high dose cotrimoxazole for Pneumocystis carinii pneumonia in AIDS be shorter? A possible solution to the problem of cotrimoxazole toxicity. J Intern Med. 1990;227:359\u201362.","journal-title":"J Intern Med"},{"key":"851_CR14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1099\/jmm.0.46552-0","volume":"55","author":"CF Linssen","year":"2006","unstructured":"Linssen CF, Jacobs JA, Beckers P, Templeton KE, Bakkers J, Kuijper EJ, Melchers WJ, Drent M, Vink C. Inter-laboratory comparison of three different real-time PCR assays for the detection of Pneumocystis jirovecii in bronchoalveolar lavage fluid samples. J Med Microbiol. 2006;55:1229\u201335.","journal-title":"J Med Microbiol"},{"key":"851_CR15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1378\/chest.119.3.844","volume":"119","author":"TL Benfield","year":"2001","unstructured":"Benfield TL, Helweg-Larsen J, Bang D, Junge J, Lundgren JD. Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia. Chest. 2001;119:844\u201351.","journal-title":"Chest"},{"key":"851_CR16","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1086\/319866","volume":"183","author":"MS Dworkin","year":"2001","unstructured":"Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis. 2001;183:1409\u201312.","journal-title":"J Infect Dis"},{"key":"851_CR17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/108729103322108139","volume":"17","author":"J Pulvirenti","year":"2003","unstructured":"Pulvirenti J, Herrera P, Venkataraman P, Ahmed N. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS. 2003;17:261\u20135.","journal-title":"AIDS Patient Care STDS"},{"key":"851_CR18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2334-8-118","volume":"8","author":"S Rahdi","year":"2008","unstructured":"Rahdi S, Alexander T, Ukwu M, Saleh S, Morris A. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis. 2008;8:118\u20139.","journal-title":"BMC Infect Dis"},{"key":"851_CR19","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1001\/archinte.1995.00430220094010","volume":"1995","author":"SM Arend","year":"1995","unstructured":"Arend SM, Kroon FP, van\u2019t Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med. 1995;1995:2436\u201341.","journal-title":"Arch Intern Med"},{"key":"851_CR20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10096-002-0758-5","volume":"21","author":"F Roblot","year":"2002","unstructured":"Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, De Gentile L, Gandji JA, Guimard Y, Lacroix C, Roblot P, Becq-Giraudon B. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002;21:523\u201331.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"851_CR21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jama.1992.03480060078034","volume":"267","author":"KA Sepkowitz","year":"1992","unstructured":"Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832\u20137.","journal-title":"JAMA"},{"key":"851_CR22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1258\/ijsa.2011.011040","volume":"22","author":"D Armstrong-James","year":"2011","unstructured":"Armstrong-James D, Copas AJ, Walzer PD, Edwards SG, Miller RF. A prognostic scoring tool for identification of patients at high and low risk of death from HIV-associated Pneumocystis jirovecii pneumonia. Int J STD AIDS. 2011;22:628\u201334.","journal-title":"Int J STD AIDS"},{"key":"851_CR23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1258\/ijsa.2010.009551","volume":"21","author":"EK Sage","year":"2010","unstructured":"Sage EK, Noursadeghi M, Evans HE, Parker SJ, Copas AJ, Edwards SG, Miller RF. Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia. Int J STD AIDS. 2010;21:288\u201392.","journal-title":"Int J STD AIDS"},{"key":"851_CR24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/thx.2009.117846","volume":"64","author":"MW Fei","year":"2009","unstructured":"Fei MW, Kim EJ, Sant CA, Jarlsberg LG, Davis JL, Swartzman A, Huang L. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax. 2009;64:1070\u20136.","journal-title":"Thorax"},{"key":"851_CR25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1550-7408.1993.tb04902.x","volume":"40","author":"E Sloand","year":"1993","unstructured":"Sloand E, Laughon B, Armstrong M, Bartlett MS, Blumenfeld W, Cushion M, Kalica A, Kovacs JA, Martin W, Pitt E, Pesanti EL, Richards F, Rose R, Walzer P. The challenge of Pneumocystis carinii culture. J Eukaryot Microbiol. 1993;40:188\u201395.","journal-title":"J Eukaryot Microbiol"},{"key":"851_CR26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrmicro1621","volume":"5","author":"CF Thomas Jr","year":"2007","unstructured":"Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5:298\u2013308.","journal-title":"Nat Rev Microbiol"},{"key":"851_CR27","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1073\/pnas.96.5.2402","volume":"96","author":"S Merali","year":"1999","unstructured":"Merali S, Frevert U, Williams JH, Chin K, Bryan R, Clarkson AB Jr. Continuous axenic cultivation of Pneumocystis carinii. Proc Natl Acad Sci USA. 1999;96:2402\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"851_CR28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/AAC.39.1.28","volume":"39","author":"TW Chin","year":"1995","unstructured":"Chin TW, Vandenbroucke A, Fong IW. Pharmacokinetics of trimethoprim\u2013sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother. 1995;39:28\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"851_CR29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1476-5381.1968.tb00475.x","volume":"33","author":"SR Bushby","year":"1968","unstructured":"Bushby SR, Hitchings GH. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother. 1968;33:72\u201390.","journal-title":"Br J Pharmacol Chemother"},{"key":"851_CR30","first-page":"42","volume":"8","author":"T Bergan","year":"1976","unstructured":"Bergan T, Brodwall EK. The pharmacokinetic profile of co-trimoxazole. Scand J Infect Dis Suppl. 1976;8:42\u20139.","journal-title":"Scand J Infect Dis Suppl"},{"key":"851_CR31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/39.1.45","volume":"39","author":"O Cirioni","year":"1997","unstructured":"Cirioni O, Giacometti A, Scalise G. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii. J Antimicrob Chemother. 1997;39:45\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"851_CR32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/infdis\/128.Supplement_3.S575","volume":"128","author":"WA Craig","year":"1973","unstructured":"Craig WA, Kunin CM. Distribution of trimethoprim\u2013sulfamethoxazole in tissues of rhesus monkeys. J Infect Dis. 1973;128:575\u20139.","journal-title":"J Infect Dis"},{"key":"851_CR33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jac\/26.6.791","volume":"26","author":"V Dubar","year":"1990","unstructured":"Dubar V, Lopez I, Gosset P, Aerts C, Voisin C, Wallaert B. The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. J Antimicrob Chemother. 1990;26:791\u2013802.","journal-title":"J Antimicrob Chemother"},{"key":"851_CR34","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1086\/313534","volume":"29","author":"R Nuesch","year":"1999","unstructured":"Nuesch R, Bellini C, Zimmerli W. Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. Clin Infect Dis. 1999;29:1519\u201323.","journal-title":"Clin Infect Dis"},{"key":"851_CR35","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","volume":"34","author":"KA Sepkowitz","year":"2002","unstructured":"Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34:1098\u2013107.","journal-title":"Clin Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-015-0851-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-015-0851-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-015-0851-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:06:09Z","timestamp":1553612769000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-015-0851-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,15]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1007\/s15010-015-0851-1","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,15]]}}}